Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 6,347 shares at $76.56 ($489K) on 2026-01-08, disclosed to the SEC on 2026-01-12.
Seasonal sale ($489k) by Executive VP AND CLO — this insider has traded PTCT in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $76.45 | 1,286 | $98K | 20.1% |
| 2 | $76.56 | 2,482 | $190K | 38.9% |
| 3 | $77.07 | 265 | $20K | 4.2% |
| 4 | $77.46 | 1,521 | $118K | 24.1% |
| 5 | $78.71 | 686 | $54K | 11.0% |
| 6 | $79.52 | 107 |
| $9K |
| 1.7% |
| Total | $77.06 avg | 6,347 | $489K | 100% |
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |